Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531986 | 0.85 | MCHR1 (0.64) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL2868187 | 0.82 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL2948427 | 0.82 | MAPK14 (0.58) | MAPK14NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5630057 | 0.81 | KMT2A (0.54) | TAS1R3TAS1R2MAPK14NPC1RAB9A | |
| SCHEMBL2060027 | 0.81 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL531505 | 0.81 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL13790808 | 0.81 | TAS1R3 (0.60) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL22468487 | 0.80 | TAS1R3 (0.60) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL22468540 | 0.80 | NPC1 (0.46) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL22468507 | 0.80 | NPC1 (0.45) | TAS1R3TAS1R1TAS1R2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198053-A1 | 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198053-A1 | 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-01 | — | — | WO | disclosed |
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| EP-2997030-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184069-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | TAS1R3 3810/4885TAS1R1 3865/4885TAS1R2 3885/4885 |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | TAS1R3 974/4885TAS1R1 611/4885TAS1R2 623/4885 |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | TAS1R3 1061/4885TAS1R1 622/4885TAS1R2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.